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Abstract
Background: Acute kidney injury (AKI) occurs frequently and adversely affects patient and kidney outcomes,
especially when its severity increases from stage 1 to stages 2 or 3. Early interventions may counteract such
deterioration, but this requires early detection. Our aim was to evaluate whether the novel renal damage biomarker
urinary chitinase 3-like protein 1 (UCHI3L1) can detect AKI stage ≥2 more early than serum creatinine and urine
output, using the respective Kidney Disease | Improving Global Outcomes (KDIGO) criteria for definition and
classification of AKI, and compare this to urinary neutrophil gelatinase-associated lipocalin (UNGAL).
Methods: This was a translational single-center, prospective cohort study at the 22-bed surgical and 14-bed
medical intensive care units (ICU) of Ghent University Hospital. We enrolled 181 severely ill adult patients who did
not yet have AKI stage ≥2 based on the KDIGO criteria at time of enrollment. The concentration of creatinine
(serum, urine) and CHI3L1 (serum, urine) was measured at least daily, and urine output hourly, in the period from
enrollment till ICU discharge with a maximum of 7 ICU-days. The concentration of UNGAL was measured at
enrollment. The primary endpoint was the development of AKI stage ≥2 within 12 h after enrollment.
Results: After enrollment, 21 (12 %) patients developed AKI stage ≥2 within the next 7 days, with 6 (3 %) of them
reaching this condition within the first 12 h. The enrollment concentration of UCHI3L1 predicted the occurrence of
AKI stage ≥2 within the next 12 h with a good AUC-ROC of 0.792 (95 % CI: 0.726–0.849). This performance was
similar to that of UNGAL (AUC-ROC of 0.748 (95 % CI: 0.678–0.810)). Also, the samples collected in the 24-h time
frame preceding diagnosis of the 1st episode of AKI stage ≥2 had a 2.0 times higher (95 % CI: 1.3–3.1) estimated
marginal mean of UCHI3L1 than controls. We further found that increasing UCHI3L1 concentrations were associated
with increasing AKI severity.
Conclusions: In this pilot study we found that UCHI3L1 was a good biomarker for prediction of AKI stage ≥2 in
adult ICU patients.
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Background
Acute kidney injury (AKI) occurs in approximately half
of adult critically ill patients [1–9]. Besides its recog-
nized adverse effect on individual patient outcomes,
both in the short- and long-term [1, 2, 4–10], AKI
causes an important socioeconomic burden ensuing
from its relationship with the development of chronic
kidney disease (CKD) [11], and end-stage renal disease
requiring renal replacement therapy (RRT) [12].
Current diagnostic and staging criteria for AKI
were defined by the Kidney Disease | Improving Global
Outcomes (KDIGO) AKI work group (Additional file 1:
Table S1) and require monitoring of two surrogate glo-
merular filtration rate (GFR) markers, i.e., serum creatin-
ine (SCr) and urine output (UO), and of the intervention
RRT [13]. As renal stress and damage to the kidneys
precede the observed decline in GFR [14], diagnostic
AKI biomarker research in the last decade has focused on
detection of these early signals [15–17]. Studies have
shown that urinary biomarkers like neutrophil gelatinase-
associated lipocalin (NGAL) [18–22], and recently the
panel tissue inhibitor of metalloproteinases 2 (TIMP-2)
and insulin-like growth factor-binding protein 7 (IGFBP7)
[21, 23, 24], can detect AKI in critically ill patients
earlier than SCr or UO, even when using the most
sensitive KDIGO criteria. In addition, these bio-
markers may also allow detection of other outcomes
such as progression of AKI, use of RRT, development
of CKD, and long-term mortality [25, 26]. The com-
plexity of the AKI syndrome and the interest in
detecting other outcomes highly warrants evaluation
of yet further candidate renal stress or damage bio-
markers aiming to find either complementary or - less
realistically - truly superior ones.
Recently, our group discovered chitinase 3-like protein
3 (CHI3L3) as a novel candidate biomarker for sepsis-
induced AKI, by urinary proteomics [27–29]. Validation
with western blot analysis confirmed the presence of
CHI3L3 in urine of septic mice with AKI, and its ab-
sence in urine of septic mice without AKI. In view of
translational research [30], two other members of the
number-18 glycoside hydrolase-family [31], i.e., chitinase
3-like protein 1 (CHI3L1) and acidic mammalian chiti-
nase (CHIA), showed similar results. Subsequently, we
found that CHI3L1 measured in urine was more dis-
criminative for the presence of AKI in human septic pa-
tients than CHIA [28].
The number-18 glycoside hydrolase-family is special in
that it comprises catalytically inactive proteins such as
chitinase-like proteins (CLP, e.g., CHI3L1) in addition to
catalytically active proteins such as chitinases [31]. These
CLPs function as lectins because they can bind, but not
hydrolyze, the glycan chitin, and therefore, represent the
chi-lectin subfamily [32, 33].
The objective of this study was first to evaluate the diag-
nostic performance of the urinary biomarker CHI3L1 for
early detection of AKI stage ≥2 in adult critically ill patients,
and then to compare this performance to that of NGAL,
which was chosen as the reference urinary biomarker.
Methods
We followed recommendations for strengthening the
reporting of observational studies in epidemiology
(STROBE) (Additional file 1: Table S2) [34]. Details of
the methods are provided in Additional file 1: Text S1
and Tables S3A-F. The methods for additional analyses
not included in the manuscript are provided in
Additional file 1: Text S2 and Tables S4A and B.
We will refer to AKI that was diagnosed and classified
by KDIGO as AKISCr/UO, while AKISCr will imply that
the KDIGO UO criteria were discarded.
Study population
We conducted a prospective cohort study at the 22-bed
surgical and 14-bed medical intensive care units (ICU)
of Ghent University Hospital from September 2012 till
August 2014. The inclusion and exclusion criteria are
shown in Table 1.
Ethics, consent and permissions
This study was approved by the Ethical Committee of
the Ghent University Hospital (Belgian registration num-
ber of the study: B670201213147), and conducted in
accordance with the declaration of Helsinki and in com-
pliance with the Good Clinical Practice Guidelines. All
patients or their legally authorized representatives pro-
vided written informed consent.
Sample collection, sample handling, and data collection
Blood and urine were collected at enrollment. The large
majority of patients i.e., 89 % was enrolled on either the
Table 1 Inclusion and exclusion criteria of the study
Inclusion criteria Exclusion criteria
Age ≥18 y AKISCr/UO stage ≥2 at time of
enrollmenta
Presence of both arterial and urinary
catheter
Expected ICU stay ≥48 h
Respiratory SOFA score ≥2 (PaO2/FiO2
< 300) or cardiovascular SOFA score
≥1 (MAP <70 mmHg or on
vasopressor(s) for at least 1 h)
CKD KDOQI stage 5 (GFR
<15 ml/min/1.73 m2 or RRT)b
Written informed consent
aBased on the Kidney Disease | Improving Global Outcomes (KDIGO) serum
creatinine (SCr) or urine output (UO) criteria for acute kidney injury (AKI).
bKidney Disease Outcomes Quality Initiative (KDOQI) [62]. CKD chronic kidney
disease, FiO2 fraction of inspired oxygen, GFR glomerular filtration rate, ICU
intensive care unit, MAP mean arterial pressure, PaO2 partial pressure of
oxygen in arterial blood, RRT renal replacement therapy, SOFA Sepsis-related
Organ Failure Assessment
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first (28 %) or second (61 %) ICU day, while the minority
i.e., 11 % was enrolled on either the third (9 %) or fourth
(2 %) ICU day. Each subject was sampled a second time
on the day of enrollment (d1) at 6 pm if the first collec-
tion was before noon. The subsequent sampling times
were at 6 am and 6 pm on d2–4, and at 6 am on d5–7
(Additional file 1: Table S3A). This is similar to the
methodology used in the hallmark study by Kashani et.
al. [21]. If the patient was discharged from the ICU be-
fore d7, the study stopped.
These paired blood and urine samples were col-
lected by standard methods and centrifuged by stan-
dard protocols. Serum and urine supernatants were
stored at −80 °C and thawed at room temperature
immediately prior to analysis. Clinical data needed to
complete the individual clinical research files were
extracted from the hospital records by study coordi-
nators. Clinical data and samples were anonymized.
JDL had access to the anonymized SCr and serum C-
reactive protein data in order to determine the appropriate
sample dilution for CHI3L1 measurement by enzyme-
linked immunosorbent assay (ELISA) (Additional file 1:
Table S3B). All other technicians were blinded to clinical
data.
Biomarker measurements
Creatinine and urinary NGAL (UNGAL) analyses were
performed externally. Creatinine concentrations were
measured with a kinetic rate-blanked Jaffé assay (com-
mercial reagents, Roche Diagnostics, Basel, Switzerland)
on a Cobas c502, while UNGAL concentrations were
measured with a particle-enhanced turbidimetric im-
munoassay (ST001-3CA, BioPorto, Hellerup, Denmark)
on a Modular P. The concentration of CHI3L1 was deter-
mined in-house with a sandwich ELISA (DC3L10, R&D
Systems, Minneapolis, MN, USA).
Both urinary CHI3L1 (UCHI3L1) and UNGAL con-
centrations were statistically analyzed as such and after
correction for urine dilution by using the ratio to urinary
creatinine (UCr). The relative change in SCr measured
at enrollment was defined as the ratio of the enrollment
SCr to reference SCr. The UO after enrollment, defined
as the mean UO in the first valid 6-h period after enroll-
ment, was determined as the mean of the 6 UO values
that were calculated each h in the first valid 6-h period
after enrollment.
Primary endpoint
The primary endpoint of the study was the develop-
ment of AKISCr/UO stage ≥2 within 12 hours (h) after
enrollment (Additional file 1: Table S1). Reference
SCr was defined as the lowest SCr value within
the last 3 months (mo) prior to enrollment. The
details for calculation of UO are outlined in Additional file
1: Text S1.
Secondary endpoints
Secondary endpoints of the study were: AKISCr/UO
stage ≥2 within 24 h and 7 days after enrollment;
AKISCr stage ≥2 within 12 h, 24 h and 7 days after
enrollment (Additional file 1: Table S1).
UCHI3L1 response to AKI
We compared samples that were collected in the
24 h preceding diagnosis of the first episode of
AKISCr/UO stage ≥2 to those that were not followed
by a first episode of AKISCr/UO stage ≥2 within the
next 24 h. For this analysis, we excluded all sam-
ples collected in the period starting from diagnosis
of the first episode of AKISCr/UO stage ≥2 till the
end of the study.
For all 21 patients who developed AKISCr/UO stage ≥2
(reference time 0 h) within 7 days after enrollment, we
documented the UCHI3L1 concentrations correspond-
ing with the time points 24 h before, 12 h before, 12 h
after, and 24 h after diagnosis of the first episode of
AKISCr/UO stage ≥2. This allowed us to investigate the
distribution of UCHI3L1 over time in patients with
AKISCr/UO stage ≥2.
We also studied the distribution of UCHI3L1 in sam-
ples corresponding with different stages of severity of
AKISCr/UO. If the total study period of 7 days was com-
pleted, 11 serum and 11 urine samples were available
per ICU patient. All available UCHI3L1 concentrations
were classified according to their AKISCr/UO stage at that
moment. As such, UCHI3L1 concentrations were di-
vided into four groups: no AKISCr/UO at the time of sam-
pling, and AKISCr/UO stages 1, 2, or 3 at the time of
sampling.
Statistical analysis
The primary analysis was based on comparison of the
areas under the receiver-operating characteristics curves
(AUC-ROC) of UCHI3L1 with those of UNGAL for pre-
dicting the defined endpoints, which was performed in
MedCalc 15.2.1 (MedCalc Software, Oostende, Belgium).
We also calculated Spearman’s coefficients of rank cor-
relation with this program. In SPSS 22 (IBM, Armonk,
NY, USA) we performed (1) mixed model analysis with
log10(UCHI3L1) as the outcome variable; diagnosis of
the first episode of AKISCr/UO stage ≥2 within 24 h after
sampling, as the predictor variable; and patient as the
random factor; (2) Fisher’s exact or the chi-square test -
the 95 % confidence interval (CI) of a proportion was
calculated with the Wilson procedure without correction
for continuity [35, 36] - and the Mann–Whitney U test;
(3) the Wilcoxon matched-pair signed-rank test; and (4)
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related-samples Friedman’s two-way analysis of variance
by ranks. Box and whisker plots were generated in
GraphPad Prism 5 (GraphPad Software, San Diego, CA,
USA). For all analyses, two-sided P values <0.05 were
considered statistically significant.
In Additional file 1: Text S1 and Tables S3C-F, we pro-
vide all details and also describe how the urinary bio-
markers were introduced into the statistical programs.
Results
The results of additional analyses not included in the
manuscript are provided in Additional file 1: Text S2
and Tables S4C-I, Additional file 2: Figure S1, Additional
file 3: Figure S2, Additional file 4: Figure S3, and Add-
itional file 5: Figure S4.
Patient characteristics and event rates
The patient flow diagram is presented in Fig. 1. Of
the 190 enrolled patients in our study cohort, 9
already fulfilled the SCr criteria for AKI stage 2 at
enrollment and were therefore excluded. In this ana-
lysis cohort (n = 181), 21 patients (12 %) developed
AKISCr/UO stage ≥2 within 7 days after enrollment.
Within 24 h AKISCr/UO stage ≥2 was met by 9 pa-
tients (5 %) and within 12 h by 6 patients (3 %). In
Table 2 the demographic information for these pa-
tients, either meeting or missing the primary end-
point, is depicted. Baseline characteristics were similar
between both groups with the exception of an older
age and a higher proportion of elective surgery in pa-
tients who developed AKISCr/UO stage ≥2 within 12 h
after enrollment. In Table 3 the distribution of pa-
tients over different SCr and UO AKI stages that
were maximally reached within 12 h, 24 h and 7 days
after enrollment is shown.
Biomarkers’ diagnostic performances
The biomarkers UCHI3L1 and UNGAL, both measured
at enrollment, were good predictors of the development
of AKISCr/UO stage ≥2 within the next 12 h, with an
AUC-ROC of 0.792 (95 % CI: 0.726–0.849) for UCHI3L1
and 0.748 (0.678–0.810) for UNGAL (P = 0.587; Fig. 2).
When UO criteria were discarded, these AUC-ROCs im-
proved to 0.877 (0.820–0.921) for UCHI3L1 and 0.865
(0.807–0.911) for UNGAL (P = 0.661). Extending our
prediction window to 24 h slightly decreased the AUC-
ROC for both biomarkers for predicting AKISCr/UO stage
≥2, while the AUC-ROC for predicting AKISCr stage ≥2
remained similar (Fig. 2). In the 7-d prediction window
both biomarkers became poor predictors of AKI stage
≥2, irrespective of the definition used. To obtain 2 expli-
cit clinical phenotypes, the AUC-ROC analyses were re-
peated excluding AKI stage 1 (comparing AKI stage ≥2
with no AKI). These showed essentially unchanged
results for UCHI3L1 and UNGAL, both measured at en-
rollment (Additional file 1: Table S5).
Correction of the urinary biomarker concentrations
for urine dilution by calculating the ratio to UCr, de-
creased the AUC-ROC for both biomarkers when diag-
nosing AKI stage ≥2 based on SCr or UO, while there
was no difference observed when diagnosing AKI stage
≥2 based on SCr alone (Table 4).
In contrast to UCHI3L1, serum CHI3L1 (SCHI3L1)
measured at enrollment was a poor predictor of
AKISCr/UO stage ≥2 within the next 12 h, with an
AUC-ROC of 0.645 (0.570–0.714). In the 24-h predic-
tion window SCHI3L1 did not predict AKISCr/UO
stage ≥2. Again, when diagnosing based on SCr alone,
the AUC-ROC for SCHI3L1 improved, i.e., 0.784
(0.717–0.842) in the 12-h and 0.830 (0.767–0.881) in
the 24-h prediction window (Table 4).
We additionally studied the discriminatory ability of
the individual KDIGO parameters, i.e., (relative change
in) SCr measured at enrollment and UO after enrollment
(Table 4). The AUC-ROC was similar for UCHI3L1, SCr
and UO. However, UCHI3L1 performed better than UO
when diagnosing AKI stage ≥2 based on SCr alone
(P = 0.034 in the 12-h and 0.022 in the 24-h prediction
window). In addition, compared to SCr, there was a clear
trend towards a better AUC-ROC for UCHI3L1, especially
when diagnosing AKI stage ≥2 based on SCr or UO within
12 h after enrollment.
Combining both urinary biomarkers as the two-
biomarker panel [UCHI3L1]•[UNGAL] did not improve
the diagnostic performance of each of these single bio-
markers for predicting either the 12-h or 24-h endpoints
(Table 5). A positive relationship between these markers
was observed, with a Spearman’s coefficient of rank cor-
relation of 0.615 (0.515–0.698) (Additional file 1:
Table S6).
With the Youden index a cutoff for UNGAL of 139 ng/ml
was identified corresponding to the reference cutoff for this
variable (>150 ng/ml [22]) (Additional file 1: Table S7).
UCHI3L1 response to AKI
Samples collected in the 24 h preceding diagnosis of the
first episode of AKISCr/UO stage ≥2 had a 2.0 times
higher (95 % CI: 1.3–3.1) estimated marginal mean of
UCHI3L1 than those not followed by a first episode of
AKISCr/UO stage ≥2 within the next 24 h. The general
time–concentration profile of UCHI3L1 showed a trend
for increasing concentrations from 24 h before, towards
diagnosis of the first episode of AKISCr/UO stage ≥2 (ref-
erence time 0 h; Fig. 3). After reference time 0 h, median
UCHI3L1 concentrations showed a decreasing trend.
Samples corresponding with AKISCr/UO stage 1 at time
of collection had higher UCHI3L1 concentrations than
those corresponding with no AKISCr/UO at the time of
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collection (P <0.001) (Fig. 4). Stage 1 and stage 2 sam-
ples had similar UCHI3L1 concentrations (P = 0.514).
Stage 3 samples again had higher UCHI3L1 concentra-
tions than stage 2 samples (P <0.001).
Discussion
We found that UCHI3L1 was a good biomarker for early de-
tection of AKI stage ≥2 in adult critically ill patients admitted
to an ICU, with a performance similar to that of UNGAL.
Fig. 1 Flow diagram of the patient selection. Acute kidney injury (AKI) was defined and classified based on the Kidney Disease | Improving Global
Outcomes serum creatinine (SCr) or urine output criteria. ICU intensive care unit, RRT renal replacement therapy, y year
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Table 2 Demographic information for patients of the analysis cohort
All patients AKISCr/UO stage ≥ 2
a No AKISCr/UO stage≥ 2
a P value
All patients 181 (100 %) 6 (3.3 %) 175 (96.7 %) NA
(1.5–7.0 %) (93.0–98.5 %)
Baseline characteristics
Sex, male 114 (63.0 %) 4 (66.7 %) 110 (62.9 %) 1.000
(55.7–69.7 %) (30.0–90.3 %) (55.5–69.7 %)
Ageb, y 60.0 (51.0–70.0) 70.5 (65.8–78.0) 59.0 (50.0–70.0) 0.040
Race, white 181 (100 %) 6 (100 %) 175 (100 %) NA
(97.9–100 %) (61.0–100 %) (97.9–100 %)
Body mass index 24 (22–28) 25 (23–28) 24 (22–28) 0.594
Reference renal function
SCr (mg/dl) 0.66 (0.52–0.79) 0.64 (0.55–0.69) 0.66 (0.51–0.79) 0.660
eGFRMDRD (ml/min/1.73 m
2) 119 (89–150) 120 (105–134) 119 (89–153) 0.975
eGFRCKD-EPI (ml/min/1.73 m
2) 102 (89–118) 98 (92–102) 103 (89–118) 0.392
Diabetes mellitus 0.787
Type I 2 (1.1 %) 0 (0.0 %) 2 (1.1 %)
(0.3–3.9 %) (0.0–39.0 %) (0.3–4.1 %)
Type II 11 (6.1 %) 0 (0.0 %) 11 (6.3 %)
(3.4–10.6 %) (0.0–39.0 %) (3.5–10.9 %)
Heart failure 1.000
NYHA class I 179 (98.9 %) 6 (100 %) 173 (98.9 %)
(96.1–99.7 %) (61.0–100 %) (95.9–99.7 %)
NYHA class II 2 (1.1 %) 0 (0.0 %) 2 (1.1 %)
(0.3–3.9 %) (0.0–39.0 %) (0.3–4.1 %)
NYHA class III 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
(0.0–2.1 %) (0.0–39.0 %) (0.0–2.1 %)
NYHA class IV 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
(0.0–2.1 %) (0.0–39.0 %) (0.0–2.1 %)
Myocardial infarction or cardiac arrestc 17 (9.4 %) 0 (0.0 %) 17 (9.7 %) 1.000
(5.9–14.5 %) (0.0–39.0 %) (6.2–15.0 %)
Malignancyc 17 (9.4 %) 1 (16.7 %) 16 (9.1 %) 0.451
(5.9–14.5 %) (3.0–56.4 %) (5.7–14.3 %)
ICU admission
Referred from 0.063
Other hospital 42 (23.2 %) 0 (0.0 %) 42 (24.0 %)
(17.7–29.9 %) (0.0–39.0 %) (18.3–30.8 %)
Emergency room 75 (41.4 %) 1 (16.7 %) 74 (42.3 %)
(34.5–48.7 %) (3.0–56.4 %) (35.2–49.7 %)
Operating room 21 (11.6 %) 1 (16.7 %) 20 (11.4 %)
(7.7–17.1 %) (3.0–56.4 %) (35.8–50.3 %)
Floor 43 (23.8 %) 4 (66.7 %) 39 (22.3 %)
(18.1–30.5 %) (30.0–90.3 %) (16.8–29.0 %)
Reason 0.038
Medical 108 (59.7 %) 3 (50.0 %) 105 (60.0 %)
(52.4–66.5 %) (18.8–81.2 %) (52.6–67.0 %)
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These findings may have important clinical and socioeco-
nomic impact. Increasing severity of AKI is associated with
increased risk of worse patient and kidney outcomes [1, 2,
4–10]. Importantly, observational and also intervention
studies showed that early AKI management can
counteract AKI deterioration, and is associated with
lower mortality and less RRT dependence at discharge
[37–44]. Consequently, even earlier identification of
AKI using a biomarker may have a much stronger ef-
fect on these outcomes.
Table 2 Demographic information for patients of the analysis cohort (Continued)
Elective surgery 13 (7.2 %) 2 (33.3 %) 11 (6.3 %)
(4.2–11.9 %) (9.7–70.0 %) (3.5–10.9 %)
Urgent surgery 60 (33.1 %) 1 (16.7 %) 59 (33.7 %)
(26.7–40.3 %) (3.0–56.4 %) (27.1–41.0 %)
First day of study
SOFA score (points) 9 (7–11) 11 (8–16) 9 (7–11) 0.189
Mechanical ventilation 122 (67.4 %) 5 (83.3 %) 117 (66.9 %) 0.665
(60.3–73.8 %) (43.6–97.0 %) (59.6–73.4 %)
Vasopressors 117 (64.6 %) 4 (66.7 %) 113 (64.6 %) 1.000
(57.4–71.2 %) (30.0–90.3 %) (57.2–71.3 %)
Infection 153 (84.5 %) 6 (100 %) 147 (84.0 %) 0.592
(78.6–89.1 %) (61.0–100 %) (77.8–88.7 %)
Infection ++d 122 (67.4 %) 6 (100 %) 116 (66.3 %) 0.179
(60.3–73.8 %) (61.0–100 %) (59.0–72.9 %)
Nephrotoxic drugs (before or at the first study day)
ACE inhibitors 25 (13.8 %) 1 (16.7 %) 24 (13.7 %) 0.596
(9.5–19.6 %) (3.0–56.4 %) (9.4–19.6 %)
ARBs 5 (2.8 %) 0 (0.0 %) 5 (2.9 %) 1.000
(1.2–6.3 %) (0.0–39.0 %) (1.2–6.5 %)
Iodinated contrast media 81 (44.8 %) 2 (33.3 %) 79 (45.1 %) 0.693
(37.7–52.0 %) (9.7–70.0 %) (38.0–52.5 %)
Aminoglycosides 6 (3.3 %) 0 (0.0 %) 6 (3.4 %) 1.000
(1.5–7.0 %) (0.0–39.0 %) (1.6–7.3 %)
Vancomycine 15 (8.3 %) 0 (0.0 %) 15 (8.6 %) 1.000
(5.1–13.2 %) (0.0–39.0 %) (5.3–13.7 %)
Diuretics 45 (24.9 %) 3 (50.0 %) 42 (24.0 %) 0.164
(19.1–31.6 %) (18.8–81.2 %) (18.3–30.8 %)
Tacrolimus 2 (1.1 %) 1 (16.7 %) 1 (0.6 %) 0.065
(0.3–3.9 %) (3.0–56.4 %) (0.1–3.2 %)
Cyclosporine 1 (0.6 %) 0 (0.0 %) 1 (0.6 %) 1.000
(0.1–3.1 %) (0.0–39.0 %) (0.1–3.2 %)
NSAIDs (chronic) 10 (5.5 %) 1 (16.7 %) 9 (5.1 %) 0.292
(3.0–9.9 %) (3.0–56.4 %) (2.7–9.5 %)
Corticosteroids (chronic) 24 (13.3 %) 1 (16.7 %) 23 (13.1 %) 0.580
(9.1–19.0 %) (3.0–56.4 %) (8.9–18.9 %)
aWithin 12 h after enrollment (primary endpoint); based on the Kidney Disease | Improving Global Outcomes (KDIGO) serum creatinine (SCr) or urine output (UO)
criteria for acute kidney injury (AKI). bDetermined at the first day of the study. cAt time of hospital or ICU admission. dSuspected bacterial infection, either leading to
arterial hypotension or organ dysfunction, or leading to shock (Additional file 1: Table S4A). Data represent number (%) (95 % CI) and median (IQR) for categorical and
continuous variables, respectively. ACE angiotensin converting enzyme, ARB angiotensin-II receptor blocker, CI confidence interval, CKD-EPI Chronic Kidney Disease
Epidemiology Collaboration, eGFR estimated glomerular filtration rate, ICU intensive care unit, IQR interquartile range, MDRD Modification of Diet in Renal Disease,
NSAID nonsteroidal anti-inflammatory drug, NYHA New York Heart Association, SOFA Sepsis-related Organ Failure Assessment
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Both UCHI3L1 and UNGAL better predicted AKI
stage ≥2 that was defined based on SCr alone versus
based on SCr or UO. These two urinary proteins are
biomarkers of renal stress or damage [45, 46], while SCr
and UO are GFR surrogates. However, UO is much
more sensitive to decline in GFR, and therefore is prob-
ably associated with less renal stress or damage than SCr,
which is supported by studies reporting that UO-based
AKI classes are associated with a lower ICU/hospital mor-
tality than SCr-based ones [9, 47, 48]. This may explain
Table 3 Distribution of patients over different KDIGO serum creatinine and urine output acute kidney injury stages maximally
reached within indicated observation periods
Time window Maximum AKI stage Number (%) UO 0a UO 1a UO 2a UO 3a Total in row
12 h SCr 0a 140 (77) ░ 11 (6) ▒ 2 (1) ▓ 0 (0) 153 (85)
24 h 122 (67) ░ 19 (10) ▒ 4 (2) ▓ 0 (0) 145 (80)
7 days 95 (52) ░ 23 (13) ▒ 2 (1) ▓ 0 (0) 120 (66)
12 h SCr 1a ░ 21 (12) ░ 3 (2) ▒ 0 (0) ▓ 0 (0) 24 (13)
24 h ░ 27 (15) ░ 4 (2) ▒ 0 (0) ▓ 0 (0) 31 (17)
7 days ░ 35 (19) ░ 7 (4) ▒ 3 (2) ▓ 0 (0) 45 (25)
12 h SCr 2a ▒ 1 (1) ▒ 1 (1) ▒ 0 (0) ▓ 0 (0) 2 (1)
24 h ▒ 0 (0) ▒ 2 (1) ▒ 0 (0) ▓ 0 (0) 2 (1)
7 days ▒ 4 (2) ▒ 4 (2) ▒ 3 (2) ▓ 0 (0) 11 (6)
12 h SCr 3a ▓ 1 (1) ▓ 1 (1) ▓ 0 (0) ▓ 0 (0) 2 (1)
24 h ▓ 2 (1) ▓ 1 (1) ▓ 0 (0) ▓ 0 (0) 3 (2)
7 days ▓ 4 (2) ▓ 1 (1) ▓ 0 (0) ▓ 0 (0) 5 (3)
12 h Total in column 163 (90) 16 (9) 2 (1) 0 (0) 181 (100)
24 h 151 (83) 26 (14) 4 (2) 0 (0) 181 (100)
7 days 138 (76) 35 (19) 8 (4) 0 (0) 181 (100)
Patients with different stages of severity of acute kidney injury (AKI) diagnosed and classified by the Kidney Disease | Improving Global Outcomes (KDIGO) serum
creatinine (SCr) or urine output (UO) criteria (AKISCr/UO) are marked with a different shaded rectangle: the darker this shade, the worse the kidney injury.
aSCr 0
represents no AKI based on the KDIGOSCr criteria. Likewise, UO 0 represents no AKI based on the KDIGOUO criteria. SCr 1/2/3 represents AKI stage 1/2/3 based on
the KDIGOSCr criteria. Likewise, UO 1/2/3 represents AKI stage 1/2/3 based on the KDIGOUO criteria
Fig. 2 Area under the receiver-operating characteristics curve (AUC-ROC) with 95 % confidence interval (CI) for urinary chitinase 3-like
protein 1 (UCHI3L1) and urinary neutrophil gelatinase-associated lipocalin (UNGAL) at enrollment for prediction of the six different
endpoints. The P value for the difference in AUC-ROC between both biomarkers for predicting acute kidney injury (AKI) stage ≥2
based on the Kidney Disease | Improving Global Outcomes (KDIGO) serum creatinine (SCr) or urine output (UO) criteria (AKISCr/UO) within 12 h after
enrollment was 0.587. In the 24-h prediction window the P value was 0.823, and in the 7-d prediction window it was 0.522. Likewise, the P value for
the difference in AUC-ROC between both biomarkers for predicting AKISCr stage ≥2 within 12 h after enrollment was 0.661. In the 24-h prediction
window the P value was 0.495, and in the 7-d prediction window it was 0.099
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the better AUC-ROCs when considering SCr alone for
diagnosis. The findings by Macedo et al. [49], who re-
ported similar ICU mortality for exclusively UO+ AKI pa-
tients (8.8 %) and (non)oliguric SCr+ AKI patients (10.4
%), appear contradictory to previous findings [9, 47, 48].
However, severity of AKI was greater in exclusively UO+
patients: >60 % of these patients were stage 2, while >70 %
of the (non)oliguric SCr+ patients were stage 1 [49]. We
also observed a partial overlap in UCHI3L1 between
AKISCr/UO stage 1 and stage 2 samples, indicating hetero-
geneity of AKI severity within KDIGO classes, which can
be partly explained by the different impact of meeting the
defined criteria for either UO alone, or SCr alone, or both
SCr and UO [9]. This could also clarify the decreased per-
formance of UCHI3L1 and UNGAL at enrollment for pre-
diction of AKISCr/UO stage ≥2 within the next 24 h. The
majority of the extra AKISCr/UO stage ≥2 patients in the 24
h observation period fulfilled UO criteria only. These
patients, therefore, probably had less renal stress or dam-
age, and consequently a low biomarker signal. Another ex-
planation could be that the hit leading to AKI is following
the biomarker measurement. This may more likely occur
when the observation period is longer [21].
The observation that the AUC-ROC for the individ-
ual KDIGO parameters, i.e., SCr and UO, were simi-
lar to those of UCHI3L1 for detection of AKI stage
≥2, warrants discussion. First, when comparing the
AUC-ROC for UO and UCHI3L1, we must take into
account that although the measurement of UO started
at enrollment, it was only completed 6 h later than
the time at which UCHI3L1 was measured. Second,
renal stress or damage may not always be reflected by
decline in GFR; vice versa, a decline in GFR may not
always reflect renal stress or damage. This may lead
to underestimation of the diagnostic performance of
UCHI3L1 in our study.
Table 4 Comparison of areas under the receiver-operating characteristics curves
Biomarker measurement Time
window
AKISCr/UO stage ≥ 2
a AKISCr stage ≥ 2
b
AUC-ROC 95 % CI P valuec AUC-ROC 95 % CI P valuec
Number = 181
▓ Enrollment UCHI3L1 12-h ▓ 0.792 ▓ 0.726–0.849 ▓ 0.877 ▓ 0.820–0.921
24-h ▓ 0.716 ▓ 0.644–0.780 ▓ 0.901 ▓ 0.848–0.940
Comparison with
Enrollment UCr-corrected UCHI3L1 12-h 0.674 0.601–0.742 0.038 0.832 0.769–0.883 0.359
24-h 0.587 0.511–0.659 0.005 0.861 0.802–0.908 0.308
Enrollment SCHI3L1 12-h 0.645 0.570–0.714 0.071 0.784 0.717–0.842 0.300
24-h 0.548 0.472–0.622 0.022 0.830 0.767–0.881 0.324
Enrollment SCr 12-h 0.624 0.549–0.695 0.113 0.732 0.662–0.795 0.363
24-h 0.639 0.565–0.709 0.406 0.766 0.697–0.826 0.278
Enrollment SCr to reference SCr ratio 12-h 0.690 0.618–0.757 0.274 0.806 0.741–0.861 0.614
24-h 0.695 0.622–0.761 0.784 0.847 0.786–0.896 0.622
▓ Enrollment UNGAL 12-h ▓ 0.748 ▓ 0.678–0.810 ▓ 0.865 ▓ 0.807–0.911
24-h ▓ 0.702 ▓ 0.630–0.768 ▓ 0.886 ▓ 0.830–0.928
Comparison with
Enrollment UCr-corrected UNGAL 12-h 0.622 0.547–0.693 0.007 0.795 0.729–0.851 0.123
24-h 0.570 0.495–0.644 0.001 0.826 0.763–0.878 0.109
Number = 180d
▓ Enrollment UCHI3L1 12-h ▓ 0.791 ▓ 0.724–0.848 ▓ 0.876 ▓ 0.819–0.921
24-h ▓ 0.715 ▓ 0.643–0.779 ▓ 0.901 ▓ 0.847–0.940
Comparison with
UO after enrollmente 12-h 0.833 0.771–0.885 0.728 0.759 0.690–0.820 0.034
24-h 0.808 0.743–0.863 0.438 0.795 0.728–0.851 0.022
aBased on the Kidney Disease | Improving Global Outcomes (KDIGO) serum creatinine (SCr) or urine output (UO) criteria for acute kidney injury (AKI). bBased on the
KDIGO SCr criteria for AKI. cThe P value is shown for the difference in the area under the receiver-operating characteristics curve (AUC-ROC). We always compared
with the AUC-ROC of the urinary biomarker (UCHI3L1 or UNGAL; marked with a shaded rectangle). dUO after enrollment could not be calculated in one patient.
eDefined as the mean UO in the first valid 6-h period after enrollment (in ml/kg/h). CI confidence interval, SCHI3L1 serum chitinase 3-like protein 1, UCHI3L1
urinary chitinase 3-like protein 1, UCr urinary creatinine, UNGAL urinary neutrophil gelatinase-associated lipocalin
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Table 5 Comparison of AUC-ROC between the two-biomarker panel [urinary chitinase 3-like protein 1]•[urinary neutrophil




a AKISCr stage ≥2
b
AUC-ROC 95 % CI P value AUC-ROC 95 % CI P value
Enrollment [UCHI3L1]•[UNGAL] 12 h 0.784 0.717–0.841 0.764c 0.874 0.817–0.919 0.879c
0.522d 0.544d
24 h 0.721 0.650–0.785 0.856c 0.899 0.845–0.939 0.877c
0.622d 0.311d
aBased on the Kidney Disease | Improving Global Outcomes (KDIGO) serum creatinine (SCr) or urine output (UO) criteria for acute kidney injury (AKI). bBased on the
KDIGO SCr criteria for AKI. cDifference in the area under the receiver-operating characteristics curve (AUC-ROC) between the two-biomarker panel and urinary
chitinase 3-like protein 1 (UCHI3L1), both measured at enrollment. dDifference in AUC-ROC between the two-biomarker panel and urinary neutrophil
gelatinase-associated lipocalin (UNGAL), both measured at enrollment
Fig. 3 Distribution of urinary chitinase 3-like protein 1 (UCHI3L1) over time in patients who developed acute kidney injury (AKI) stage ≥2 based on the
Kidney Disease | Improving Global Outcomes (KDIGO) serum creatinine (SCr) or urine output (UO) criteria (AKISCr/UO) within 7 days after enrollment. The
reference time 0 h represents time of diagnosis of the first episode of AKISCr/UO stage ≥2. At time 24 h, a UCHI3L1 concentration was available for 14 of
these 21 patients. Likewise, 13 values were available at time 12 h, 19 at reference time 0 h, 14 at time 12 h, and 12 at time 24 h
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We found a trend for increased UCHI3L1 concentra-
tions in the 24 h preceding AKI, and for decreased
concentrations afterwards. However, it should be empha-
sized that after meeting AKISCr/UO stage ≥2, the individ-
ual time–concentration profiles of AKISCr/UO differed
widely between patients: some remained in the same se-
verity stage, some deteriorated and others ameliorated
(data not shown). The number of patients observed in
this pilot study also precludes firm conclusions.
This is the first translational study demonstrating that
UCHI3L1 predicts the occurrence of AKI stage ≥2 in
adult critically ill patients [28]. Schmidt et al. independ-
ently showed that UCHI3L1 predicts the occurrence of
delayed graft function in adult patients who receive
deceased-donor kidney transplants [46]. In their preclin-
ical study, these authors reported that the transcription
of the CHI3L1 gene is significantly upregulated in the
mouse kidney after ischemia/reperfusion (I/R) injury
with increased excretion of its protein in urine. These
mRNA and protein levels correlated with the degree of
kidney injury and were at earliest measured on the first
day after I/R, when SCr values had already peaked. Re-
cently, the same group also studied a cohort of hospital-
ized patients who had AKI, and found that UCHI3L1
was associated with the composite outcome of AKI pro-
gression and in-hospital death [50].
We must speculate on the source of CHI3L1. Upon
renal stress or damage, this protein is secreted by mac-
rophages within the kidney [46], while NGAL is secreted
by specific cells of the distal nephron [45]. Another
source for the urine component of NGAL is the circulat-
ing plasma pool [51]. We speculate that the same is true
for CHI3L1 as this protein has an apparent molecular
weight of ±39–40 kDa [52, 53], and as within the group
of patients with no AKI (in the 7-d prediction window) a
concomitant very high level of SCHI3L1 was observed
more in those with an increased than with a normal
UCHI3L1 at enrollment (Additional file 1: Table S8).
Additionally, we speculate that CHI3L1 binds to the
megalin receptor for tubular reabsorption. This implies
that NGAL and CHI3L1 can each indirectly affect the
urinary concentration of the other, as they are then com-
petitors [51].
Similar to NGAL, CHI3L1 is also stored in the sec-
ondary granules of circulating neutrophils [54–56].
This could implicate that in the urine of patients with
a urinary tract infection (UTI), CHI3L1 is increased
too [57]. Although data on UCHI3L1 in UTI patients
are missing, proteome profiling of human neutrophils
suggests that this issue is less relevant for UCHI3L1
[56], which agrees with the reported 12 pg NGAL
and 0.16 pg CHI3L1 per leukocyte [57, 58].
Surprisingly, only in 2013 He et al. investigated the
possibility that the CLP CHI3L1 mediates its bio-
logical effects through receptor binding, and identified
interleukin-13 receptor α2 as the binding partner
[59]. These biological effects include inhibition of
apoptosis in renal epithelial cells [46, 59], and inhibition of
pyroptosis and interleukin-1β production in macrophages
[59, 60]. These innate immune cells play an important role
in both kidney injury and repair [61].
Our study has important limitations. First, this is a
single-center study conducted in surgical and medical
ICUs. Although the baseline characteristics of patients,
the observed outcomes, and the NGAL cutoff based on
the Youden index suggest that the patients included are
representative of ICUs in developed Western countries,
these data remain to be confirmed in other centers and
in different types of ICU. Second, only a limited number
of patients reached the primary endpoint, which can be
partly explained by selection bias, i.e., not asking (legally
authorized representatives of ) the most critically ill pa-
tients for consent. Yet, this is a typical and hence, rather
unavoidable feature of prospective studies like this [21].
The restricted period for observation of AKI stage ≥2
Fig. 4 Distribution of urinary chitinase 3-like protein 1 (UCHI3L1) in
samples corresponding with different stages of severity of acute
kidney injury (AKI) based on the Kidney Disease | Improving Global
Outcomes serum creatinine (SCr) or urine output (UO) criteria (AKISCr/UO)
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certainly contributes to the low event rate as well.
Therefore, we included all 21 patients (12 %) who devel-
oped AKISCr/UO stage ≥2 within 7 days after enrollment
in the mixed model analysis. Third, following the
KDIGO guidelines [13], reference SCr was defined as
the lowest SCr value within the last 3 mo prior to enroll-
ment. This method is prone to bias, as blood draws for
SCr measurement tend to be performed more often
when patients are in hospital or sick, thereby not reflect-
ing true baseline kidney function. Fourth, we did not
measure urinary [TIMP-2]•[IGFBP7], a two-biomarker
panel found to be superior to UNGAL [21, 23, 24], be-
cause it was not available at the start of our study.
Conclusions
In summary, we demonstrated that UCHI3L1 measured
in critically ill patients admitted to an ICU, predicted the
occurrence of AKI stage ≥2 within a 12-h or 24-h
observation period. The results of this pilot study need
confirmation in different settings and in larger patient
cohorts.
Key messages
 The urinary proteome contains very relevant
information: following an acute renal attack,
CHI3L1 will appear in urine, indicating damage to
the kidneys.
 In this pilot cohort of critically ill patients admitted
to an ICU, the UCHI3L1 response predicted
development of AKI stage ≥2 within a 12-h or 24-h
period.
 The higher the concentration of UCHI3L1, the
greater the severity of AKI.
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